AKT1

A gene on chromosome 14q32.32|14q32.32 that encodes protein kinase B (PKB), a serine-threonine protein kinase that is rapidly and specifically activated by platelet-derived growth factor through phosphatidylinositol 3-kinase. PKB plays a key role in regulating cell survival, insulin signalling, angiogenesis, tumour formation and growth factor-induced neuronal survival. Activated AKT1 phosphorylates and inactivates components of the apoptotic machinery.

Mentioned in ?

References in periodicals archive ?

0001) for the SOS cascade (BDNF, SOS1, SOS2, and SYN1), whereas for the AKT cascade (BDNF, AKT1, AKT2, and AKT3) associations between gene expression and [PM.

In utero fine particle air pollution and placental expression of genes in the brain-derived neurotrophic factor signaling pathway: an environage birth cohort study

As with the other samples in that study, the sequenced amplicons were shown to have multiple artifacts in exons of the AKT1 and BRAF genes.

Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates

The study to be published in the Journal of Cellular Biochemistry on November 1, 2009 (Volume 108, pages 832-838 in Issue 4), also found that the combined treatment of AKT1 AO with cytotoxic drugs showed even greater anti-tumor activity in human renal carcinoma cell line.

New Animal Study Featured in the Journal of Cellular Biochemistry Supports Rexahn's Archexin[TM] as Potent Inhibitor of Human Cancer Cell Growth

There were no differences between UPSC and EOS-C in the rates of mutation of APC, ATM, BRAF, and AKT1.

Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers

Identify the most promising approaches to kinase modulation in cancer and other diseases by examining drug targets including ABL1, EGFR, ERBB2, FLT3, KIT, PDGFRA, PDGFRB, FLT1, FLT4, KDR, JAK2, MET, AKT1, CDC2, CDK2, AURKA, AURKB, PLK1, FRAP1 and PIK3CA.

Research and Markets: The Global Market for Kinase-Targeted Drugs is Forecast to Grow by 18% Per Annum, from $13bn in 2008 to $35bn in 2013

We were pleased to find higher incidences of the AKT1, KRAS, PIK3CA, and TP53 mutations, which suggest potential druggable mutations and areas of research for further therapy development.

Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer

The AKT protein family consists of the AKT1 and AKT2 isoforms, which play distinct roles in cell migration.

Flavonoids promoting HaCat migration: II. Molecular mechanism of 4',6,7-trimethoxyisoflavone via NOX2 activation

60) Mutations in AKT1 (v-akt murine thymoma viral oncogene homologue 1) gene, which encodes protein kinase B have been identified in several solid malignancies including breast, colon, and ovarian carcinomas.

Molecular profiling in non-small cell lung cancer: a step toward personalized medicine

Specifically, NGS revealed mutations in the PIK3CA (33%), FBXW7 (14%), and AKT1 (2%) genes, and IHC detected loss of the PTEN protein in 54% of samples, suggesting that agents targeting the PI3-kinase pathway may be useful in tumors harboring these mutations.

Caris Molecular Intelligence(TM) Identifies Therapeutic Options, Including Novel Immunotherapeutics, for Patients with Rare, Advanced Anal Squamous Cell Carcinoma

Among these are KRAS, HER2/neu, BRAF, NRAS, MEK1, and AKT1.

Worldwide overview of the current status of lung cancer diagnosis and treatment

Tumor samples from 288 patients, which had previously been analyzed for KRAS exon 2 mutations, were analyzed in this study for mutations in nine genes: KRAS (exon 3), NRAS, BRAF, PIK3CA, PTEN, AKT1, EGFR, beta-catenin (CINN1B) and TP53.

Analysis of Vectibix(R) Study Using New Gene Technology Helps to Advance Prospects for Personalized Medicine

INDIANAPOLIS, July 4 /PRNewswire-FirstCall/ -- Researchers from Eli Lilly & Company and the Phoenix-based Translational Genomics Research Institute (TGen) today announced finding a novel recurring mutation of the gene AKT1 in breast, colorectal and ovarian cancers.

Researchers Identify Genetic Mutation That May Alter Patients' Response to Cancer Therapeutics

CITE

Site: Follow: Share:

Open / Close